LOS ANGELES, June 25, 2018 /PRNewswire/ -- CytRx Corporation
(NASDAQ:CYTR), a biopharmaceutical research and development company
specializing in oncology, today announced that it has been added to
the Russell Microcap® Index, effective upon the market
opening today, Monday, June 25,
2018.
"We are honored to be added to the Russell Microcap®
Index," said Eric Curtis, CytRx's President and Chief
Operating Officer. "We believe our inclusion highlights the growth
CytRx has made as a company and the progress our newly launched
private subsidiary, Centurion BioPharma Corporation, continues to
make in advancing its LADR™ technology for the benefit
of patients in need."
About the Russell Indexes
The Russell indexes are broadly referenced as benchmarks by
active investment strategists and institutional investors for index
funds. The Russell Microcap® Index is a
capitalization-weighted index of 2,000 small cap and micro cap
stocks that captures 1,000 small-cap companies in the Russell
2000®, in addition to 1,000 other U.S.-based stocks. The
index is reconstituted yearly.
For more information on the Russell Microcap® Index
and the Russell US Indexes reconstitution, go to the "Russell
Reconstitution" section on the FTSE Russell website.
About CytRx Corporation
CytRx Corporation (Nasdaq: CYTR) is a biopharmaceutical company
with expertise in discovering and developing new therapeutics to
treat patients with cancer. CytRx's most advanced drug
conjugate, aldoxorubicin, is an improved version of the widely used
anti-cancer drug doxorubicin and has been out-licensed to NantCell,
Inc. CytRx Corporation's website is www.cytrx.com.
About Centurion BioPharma Corporation
CytRx's wholly owned subsidiary, Centurion BioPharma
Corporation, is focused on advancing a portfolio of novel,
anti-cancer drug candidates that employ its LADR™
(Linker Activated Drug Release) technology, a discovery engine
designed to leverage the Company's expertise in albumin biology and
linker technology for the development of a new class of potential
breakthrough anti-cancer therapies. A critical element of the
LADR™ platform is its ability to bind anti-cancer
molecules to albumin, the most ubiquitous protein in human blood
plasma, and then to release the highly potent cytotoxic payload at
the tumor site. This technology allows for the delivery of higher
doses of drug directly to the tumor, while avoiding much of the
off-target toxicity observed with the parent molecules. The website
is www.centurionbiopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements. Such
statements involve risks and uncertainties that could cause actual
events or results to differ materially from the events or results
described in the forward-looking statements, including risks and
uncertainties relating to the ability of NantCell, Inc., to obtain
regulatory approval for its products that use aldoxorubicin; the
ability of NantCell, Inc., to manufacture and commercialize
products or therapies that use aldoxorubicin; the amount, if any,
of future milestone and royalty payments that we may receive from
NantCell, Inc.; Centurion BioPharma Corporation's ability to
develop new ultra-high potency drug candidates based on its
LADR™ technology platform; our ability to attract
potential licensees; and other risks and uncertainties described in
the most recent annual and quarterly reports filed by CytRx with
the Securities and Exchange Commission and current reports filed
since the date of CytRx's most recent annual report. All
forward-looking statements are based upon information available to
CytRx on the date the statements are first published. CytRx
undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Investor Relations Contact:
Argot Partners
Michelle Carroll
(212) 600-1902
michelle@argotpartners.com
View original
content:http://www.prnewswire.com/news-releases/cytrx-corporation-joins-russell-microcap-index-300671120.html
SOURCE CytRx Corporation